2-氯-3,6-二氟苯甲醛 | 261762-39-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲醛系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3,6-二氟苯甲醛
• 英文名称: 2-chloro-3,6-difluorobenzaldehyde
• CAS: 261762-39-4
• 化学式: C₇H₃ClF₂O
• mdl: MFCD01631443
• 分子量: 176.55
• InChiKey: KPYBGKSDBNMHTO-UHFFFAOYSA-N

物化性质

• 熔点：
  46-50 °C (lit.)
• 沸点：
  206.4±35.0℃ (760 Torr)
• 密度：
  1.453±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  230 °F
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2913000090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  保存方法：将物品存放在密闭、阴凉、通风干燥的地方。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Chloro-3,6-difluorobenzaldehyde
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 261762-39-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C7H3ClF2O
Molecular Weight : 176,55 g/mol
CAS-No. : 261762-39-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Chloro-3,6-difluorobenzaldehyde
CAS-No. 261762-39-4 Skin Irrit. 2; Eye Irrit. 2; STOT <= 100 %
SE 3; H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Chloro-3,6-difluorobenzaldehyde
CAS-No. 261762-39-4 Xi, R36/37/38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Handle and store under inert gas. Air sensitive.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 46 - 50 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point 110 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
Air
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit. Eye irritation
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
Xi Irritant
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

简介

2-氯-3,6-二氟苯甲醛是一种医药中间体，可通过将2-氯-1,4-二氟苯在-78℃下与二异丙基氨基锂反应后，再与N,N-二甲基甲酰胺反应得到。

用途

该化合物作为醛类衍生物，主要用于制备下游产物2-氯-3,6-二氟苯甲腈。

制备

将1.78克（12.0毫摩尔）的2-氯-1,4-二氟苯溶解于50毫升四氢呋喃中，并冷却至-78℃。随后加入1.8M的二异丙基氨基锂溶液7.3毫升（13.2毫摩尔）。在-78℃下搅拌30分钟后，滴加1.05克（14.4毫摩尔）N,N-二甲基甲酰胺。继续搅拌15分钟后再加入3毫升乙酸和100毫升水，将混合物升温至室温。用乙酸乙酯萃取后，有机相经1M盐酸溶液和盐水洗涤，并用硫酸镁干燥。最终在减压下浓缩得到2-氯-3,6-二氟苯甲醛，收率为理论值的71%。

反应信息

• 作为反应物：
  描述：

  2-氯-3,6-二氟苯甲醛 在 sodium methylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以85%的产率得到2-氯-3-氟-6-甲氧基苯甲醛
  参考文献：
  名称：

  [EN] FUSED BICYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASES BICYCLIQUES FUSIONNÉS

  摘要：

  式(I)的化合物，其药用盐，合成方法，中间体，配方以及使用它们进行疾病治疗的方法，包括治疗癌症，如至少部分由MET、RON、ALK、IR或IGF-1R中的至少一个驱动的肿瘤。本摘要不限制该发明。

  公开号：

  WO2012158658A1
• 作为产物：
  描述：

  2,5-二氟氯苯 、 N,N-二甲基甲酰胺 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 以71%的产率得到2-氯-3,6-二氟苯甲醛
  参考文献：
  名称：

  (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

  摘要：

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血和血液性关节积血后的滑膜炎和软骨损伤等疾病或医疗干预有关。

  公开号：

  US20150126449A1

文献信息

• Secondary Amines as Renin Inhibitors
  申请人：Bezencon Olivier

  公开号：US20090176823A1

  公开（公告）日：2009-07-09

  The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  这项发明涉及公式（I）的新型二级胺衍生物及其作为药物组成物中的活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组成物，特别是它们作为肾素抑制剂的用途。
• Indol-3-yl derivatives
  申请人：——

  公开号：US20040138284A1

  公开（公告）日：2004-07-15

  Indol-3-yl derivatives of the general formula I 1 in which A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 , n and m are as defined in Patent Claim 1, and their physiologically acceptable salts or solvates are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, macular degenerative disease, diabetic retinopathy, infections and restenosis after angioplasty or in pathological processes maintained or propagated by angiogenesis.

  通用公式I的Indol-3-基衍生物 其中A、B、X、R1、R2、R3、R4、R5、n和m的定义如专利权要求书中所定义 1， 及其生理上可接受的盐或溶剂是整合素抑制剂，可用于对抗血栓形成、心肌梗死、冠心病、动脉硬化、炎症、肿瘤、骨质疏松症、风湿性关节炎、黄斑变性疾病、糖尿病视网膜病变、感染以及血管成形术后的再狭窄或由血管生成维持或传播的病理过程。
• [EN] SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING<br/>[FR] THIOPHÈNES CONDENSÉS SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS DE STING
  申请人：CTXT PTY LTD

  公开号：WO2019219820A1

  公开（公告）日：2019-11-21

  A compound of formula (I), wherein: R1 is selected from (i) H, (ii) C3-6cycloalkyl, (iii) C3-7heterocyclyl optionally substituted with a group selected from: methyl and ester, and (iv) linear or branched C1-4alkyl optionally substituted with a group selected from: alkoxy, amino, amido, acylamido, acyloxy, alkyl carboxyl ester, alkyl carbamoyl, alkyl carbamoyl ester, phenyl, phosphonate ester, C3-7heterocyclyl optionally substituted with a group selected from methyl and oxo, and a naturally occurring amino acid, optionally N-substituted with a group selected from methyl, acetyl and boc; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC, and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and CH2NMe2; the remainder of RA, RB, RC, and RD, (if present) are H; Y is O, NH or CH2; RY is selected from: (RYA) and (RYB).

  化合物的化学式（I），其中：R1选自（i）H，（ii）C3-6环烷基，（iii）C3-7杂环烷基，可选择地取代为：甲基和酯，以及（iv）线性或支链C1-4烷基，可选择地取代为：烷氧基，氨基，酰胺基，酰氧基，烷基羧酯，烷基氨基，烷基氨基酯，苯基，磷酸酯，C3-7杂环烷基，可选择地取代为甲基和氧代基，以及一种天然氨基酸，可选择地N-取代为：甲基，乙酰基和boc；A1为CRA或N；A2为CRB或N；A3为CRC或N；A4为CRD或N；其中A1，A2，A3和A4中最多有两个可以是N；RA，RB，RC和RD中的一个或两个（如果存在）选自H，F，Cl，Br，Me，CF3，环丙基，氰基，OMe，OEt，CH2OH，CH2OMe和CH2NMe2；RA，RB，RC和RD的其余部分（如果存在）为H；Y为O，NH或CH2；RY选自：（RYA）和（RYB）。
• Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
  作者：Olivier Bezençon、Daniel Bur、Thomas Weller、Sylvia Richard-Bildstein、Luboš Remeň、Thierry Sifferlen、Olivier Corminboeuf、Corinna Grisostomi、Christoph Boss、Lars Prade、Stéphane Delahaye、Alexander Treiber、Panja Strickner、Christoph Binkert、Patrick Hess、Beat Steiner、Walter Fischli

  DOI：10.1021/jm900022f

  日期：2009.6.25

  Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent

  从已知的哌啶肾素抑制剂开始，合理设计和制备了一系列新的3,9-二氮杂双环[3.3.1]壬烯衍生物。优化二氮杂双环烯模板的位置3、6和7导致有效的肾素抑制剂。在6和7位上连接的取代基对于这些化合物对肾素的结合亲和力是必不可少的。引入在3位上连接的取代基不会改变结合亲和力，但可以调节ADME性质。我们的努力导致发现抑制肾素的化合物（+）- 26g，在缓冲液中的IC 50为0.20 nM，在血浆中的IC 50为19 nM。讨论了该化合物和其他类似化合物的药代动力学特性。化合物（+）- 26克 在大鼠中被很好地吸收，在体内10 mg / kg时有效。
• [EN] CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS PYRROLOPYRIDINE ET PYRROLOPYRIMIDINE À SUBSTITUTION CYCLOBUTYLE UTILISÉS COMME INHIBITEURS DES JAK
  申请人：INCYTE CORP

  公开号：WO2012068450A1

  公开（公告）日：2012-05-24

  The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了式I的环丁基取代的吡咯并嘧啶和吡咯并吡啶：其中X、Y、Z、L、A、R5、n和m如上定义，以及它们的组合物和使用方法，用于调节Janus激酶（JAKs）的活性，并且在治疗与JAKs活性相关的疾病中是有用的，例如炎症性疾病、自身免疫疾病、癌症和其他疾病。